BridgeBio's Attruby Shows Significant Reduction in Cardiovascular Mortality in ATTR-CM Patients
ByAinvest
Saturday, Aug 30, 2025 11:05 am ET1min read
BBIO--
The study, part of the ATTRibute-CM open-label extension (OLE), demonstrated a 44% hazard reduction in CVM, setting a new standard for CVM outcomes in ATTR-CM patients. This reduction was observed in both ATTRv-CM (variant) and ATTRwt-CM (wild-type) patients, highlighting the drug's broad applicability [1].
Additionally, Attruby showed a 46% hazard reduction in the risk of the composite outcome of CVM or first cardiovascular hospitalization (CVH) through 42 months. The drug also demonstrated higher rates of disease stabilization or improvement versus disease progression, as reflected in changes from baseline in NT-proBNP and NAC Stage [1].
The study's results underscore the long-term clinical benefits of Attruby for reducing CVM in ATTR-CM patients, emphasizing the importance of early and sustained treatment. The drug has received approvals from the U.S. FDA as Attruby and the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency as BEYONTTRA [1].
BridgeBio Pharma, a biopharmaceutical company focused on genetic diseases, presented these findings. The company's pipeline includes several development programs ranging from early science to advanced clinical trials. BridgeBio was founded in 2015 and is committed to delivering transformative medicines to patients suffering from genetic diseases [2].
References:
[1] https://www.morningstar.com/news/globe-newswire/9520845/acoramidis-demonstrates-statistically-significant-reduction-in-cardiovascular-mortality-cvm-through-month-42-of-the-attribute-cm-open-label-extension
[2] https://www.bridgebio.com
BridgeBio Pharma's Attruby (acoramidis) showed significant reduction in cardiovascular mortality in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) in a new open-label study. At 42 months post-randomization, Attruby led to a 44% reduction.
BridgeBio Pharma's Attruby (acoramidis) has shown promising results in reducing cardiovascular mortality (CVM) among individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) in a recent open-label study. The findings, presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain, indicate a significant reduction in CVM through 42 months post-randomization [1].The study, part of the ATTRibute-CM open-label extension (OLE), demonstrated a 44% hazard reduction in CVM, setting a new standard for CVM outcomes in ATTR-CM patients. This reduction was observed in both ATTRv-CM (variant) and ATTRwt-CM (wild-type) patients, highlighting the drug's broad applicability [1].
Additionally, Attruby showed a 46% hazard reduction in the risk of the composite outcome of CVM or first cardiovascular hospitalization (CVH) through 42 months. The drug also demonstrated higher rates of disease stabilization or improvement versus disease progression, as reflected in changes from baseline in NT-proBNP and NAC Stage [1].
The study's results underscore the long-term clinical benefits of Attruby for reducing CVM in ATTR-CM patients, emphasizing the importance of early and sustained treatment. The drug has received approvals from the U.S. FDA as Attruby and the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency as BEYONTTRA [1].
BridgeBio Pharma, a biopharmaceutical company focused on genetic diseases, presented these findings. The company's pipeline includes several development programs ranging from early science to advanced clinical trials. BridgeBio was founded in 2015 and is committed to delivering transformative medicines to patients suffering from genetic diseases [2].
References:
[1] https://www.morningstar.com/news/globe-newswire/9520845/acoramidis-demonstrates-statistically-significant-reduction-in-cardiovascular-mortality-cvm-through-month-42-of-the-attribute-cm-open-label-extension
[2] https://www.bridgebio.com
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet